Covance Inc. (Princeton, NJ) has completed an additional 8,000-sq. ft. to its biotechnology services facility in Harrogate, UK.
Covance Inc. (Princeton, NJ) has completed an additional 8,000-sq. ft. to its biotechnology services facility in Harrogate, UK. The expanded facility includes new Class 10,000 laboratories and equipment for biopotency, molecular biology, and protein chemistry services.
The expansion enables the company to offer new services, such as cGMP DNA sequencing, and viral clearance, PCR-based mycoplasma, and sterility testing. The company also has tripled the capacity of its molecular biology, safety testing, and bioassay service lines, and introduced a purpose-designed mycoplasma testing facility separation from the main operational areas.
The Harrogate site also recently received a current good manufacturing practice (cGMP) manufacturing license from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the manufacture of master cell banks and working cell banks. Following a recent change in policy, the MHRA now requires a cGMP license for cell banking because it considers this activity to be the starting point of the manufacturing process. As part of the license, a Qualified Person now formally releases the manufactured cell bank as part of the review and verification processes.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.